Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

Forget Cash: Hold These 2 Dividend Beasts in Your TFSA

Published 2019-09-07, 05:45 p/m
Updated 2019-09-07, 06:06 p/m
© Reuters.

An August study released by Statistics Canada revealed that more than 40% of Canadian families now possess a tax-free savings account. This is encouraging, as the mass adoption of the account had been slow going since its inception in 2009. Less encouraging is how TFSAs are currently being utilized.

The report also revealed that 42% of TFSA-holders primarily hold cash. In previous articles I’d discussed strategies that Canadians can pursue for their TFSA. Even conservative investors should look to take advantage of the tax-free compounding afforded by this account.

Holding cash removes the biggest benefit of this investment vehicle. Some may pursue a high-interest savings account, but even the interest earned in these accounts is small and rarely keeps up with inflation.

Investors holding cash may be risk-averse, so today we’ll look at two dependable equities that offer big dividend payouts. These can be fantastic holds in a TFSA, as investors can gobble up steady tax-free income over a long period while also feasting on tax-free capital gains.

Canadian Imperial Bank of Commerce Canadian Imperial Bank of Commerce (TSX:CM)(NYSE:CM) stock has climbed 3.9% in 2019 so far. The bank posted a solid third quarter in late August as profit rose 2% year over year to $1.4 billion.

Its Canadian personal and small business segment reported strong growth in the quarter as the broader domestic economy has looked healthier moving into the fall.

I’d recommended CIBC stock as a discount buy before its earnings release. Why is it attractive to newcomers? Similar to its peers, CIBC has never missed a dividend payment since it implemented one in the 19th century. It has achieved dividend growth for eight consecutive years. In the third quarter, CIBC hiked its quarterly dividend to $1.44 per share, presenting an attractive 5.6% yield.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Shares of CIBC even offer favourable value with a price-to-earnings ratio of 9 and a price-to-book of 1.3.

Enbridge Enbridge (TSX:ENB)(NYSE:ENB) stock has increased 10% in 2019 even though it has faced headwinds in the energy sector. Its earnings have been promising of late, and in the second quarter it reported adjusted earnings of $1.35 billion or $0.67 per share compared to $1.09 billion, or $0.65 per share in the prior year.

The company is attractive to conservative investors because of its wide economic moat, deep project pipeline, and its long history of dividend growth. Enbridge has hiked its dividend for 23 consecutive years.

It last increased its quarterly payout to $0.738 per share, which represents a tasty 6.6% yield. Enbridge is aiming for a dividend increase between 8-10% in 2021, but this trend may be adjusted lower as we move into the next decade. In any case, Enbridge still offers an attractive yield.

Shares of Enbridge boast a P/E ratio of 15.9 and a P/B of 1.4, both in favourable territory.

Fool contributor Ambrose O'Callaghan has no position in any of the stocks mentioned. The Motley Fool owns shares of Enbridge. Enbridge is a recommendation of Stock Advisor Canada.

The Motley Fool’s purpose is to help the world invest, better. Click here now for your free subscription to Take Stock, The Motley Fool Canada’s free investing newsletter. Packed with stock ideas and investing advice, it is essential reading for anyone looking to build and grow their wealth in the years ahead. Motley Fool Canada 2019

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

This Article Was First Published on The Motley Fool

Latest comments

Cure contre le VIH avec phytothérapie, le docteur Ahmed Usman a guéri mes trois années de VIH avec phytothérapie, je suis tombé sur le témoignage de son patient sur Internet et je l'ai contacté par courrier électronique. Après de nombreuses discussions, il a envoyé sa phytothérapie à mon domicile. et avec sa prescription, j’ai pris le médicament à base de plantes pendant 21 jours, j’ai découvert les modifications sur mon corps, je ne suis plus malade et mes organes sont très actifs, j’ai fait un test et mon résultat a été négatif. Contactez-le pour votre traitement, drahmedusman 5104 @ gmail.com ou Whatsapp / appelez +2348064460510, il a guéri à base de plantes pour le virus de l'herpès et le cancer.
for disclosure u own Suncor
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.